

0001193125-24-2588046-K Apollomics Inc. 2024111420241114172549172550172550 0 0001193125-24-258804 6-K 1
20241114 20241114 20241114 Apollomics Inc. 0001944885 2834 000000000 1231 6-K 34 001-41670 241464491 989
EAST HILLSDALE BLVD. STE 220 FOSTER CITY CA 94404 1-650-209-4055 989 EAST HILLSDALE BLVD. STE 220
FOSTER CITY CA 94404 6-K 1 d912284d6k.htm 6-K 6-K Â UNITED STATES SECURITIES AND EXCHANGE
COMMISSION Washington, D.C. 20549 Â FORM 6-K Â REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024
Commission file number: 001-41670 Â Apollomics Inc. (Exact name of registrant as specified in its charter) Â Not
Applicable (Translation of registrantâ€™s name into English) 989 E. Hillsdale Blvd., Suite 220 Foster City, California
94404 (Address of principal executive office) Â Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F. Form 20-Fâ€,â˜â€fâ€fâ€fForm 40-Fâ€,â˜ Â Results of the 2024
Extraordinary General Meeting of Shareholders On NovemberÂ 14, 2024, Apollomics Inc., an exempted company
incorporated with limited liability under the laws of the Cayman Islands (the â€œCompanyâ€), held its Extraordinary
General Meeting of Shareholders (the â€œMeetingâ€). At the Meeting, the holders of 40,155,852 shares were
represented of the 110,266,527 shares outstanding as of the record date of OctoberÂ 21, 2024, constituting a quorum.
At the Meeting, the Companyâ€™s shareholders approved the following proposals, which are described in more detail
in the Companyâ€™s proxy statement, mailed to shareholders on or about NovemberÂ 1, 2024. The final voting results
for each matter submitted to a vote of shareholders at the meeting are as follows: Proposal No.Â 1. Reverse Share Split
To approve by an ordinary resolution, that the Company effect a reverse share split to the Companyâ€™s authorised,
issued and outstanding shares by way of a consolidation at an exchange ratio of not less than twenty-five to one (25:1)
and up to one hundred to one (100:1) (the â€œMaximum RS Ratioâ€ and each ratio within the range and including the
Maximum RS Ratio, a â€œRS Ratioâ€) such that the number of authorised, issued and outstanding shares is decreased
by the precise RS Ratio (the â€œFinal RS Ratioâ€), being the RS Ratio determined by the Directors from within the
range of RS Ratios) and the par value of each authorised, issued and outstanding share is increased by the Final RS
Ratio (collectively, the â€œReverse Share Splitâ€), with such Reverse Share Split to be effected at such time and date,
if at all, and at the Final RS Ratio, as determined by the Directors in their discretion within 12 months of obtaining the
requisite shareholder approval for the Reverse Share Split (the â€œEffective Timeâ€), with the effect of such Reverse
Share Split, and subject to adjustment pending the Directorsâ€™ determination of the Final RS Ratio, being that the
authorised share capital of the Company would be altered from US\$65,000 divided into 650,000,000 shares of a par
value of US\$0.0001 each, comprising (i) 500,000,000 class A ordinary shares, (ii) 100,000,000 class B ordinary shares
and (iii) 50,000,000 preference shares, of which 3,000,000 preference shares are designated as series A preferred
shares to US\$65,000 divided into as low as 6,500,000 shares (for an RS Ratio of 100:1) of a par value of US\$0.01, and
as high as 26,000,000 shares (for an RS Ratio of 25:1) of a par value of US\$0.0025, with effect from the Effective Time.
Â For Â Against Â Abstain 36,064,857 Â 4,086,504 Â 4,491 Proposal No.Â 2. Share Capital Increase To
approve by an ordinary resolution, that if the Reverse Share Split is implemented, with effect immediately after the
Reverse Share Split at the Final RS Ratio determined by the Directors, that the authorised share capital of the Company
be increased from US\$65,000 divided into as low as 6,500,000 shares (for an RS Ratio of 100:1) of a par value of
US\$0.01 with effect from the Effective Time to up to US\$1,300,000, divided into 130,000,000 shares, comprising (i)
100,000,000 class A ordinary shares, (ii) 20,000,000 class B ordinary shares and (iii) 10,000,000 preference shares, a
par value of US\$0.01 each (the â€œAuthorised Share Capital Increaseâ€). Â For Â Against Â Abstain 26,597,393
Â 13,544,252 Â 14,207 Proposal No.Â 3. Adjournment Proposal To approve by an ordinary resolution, that the
adjournment of the Meeting to a later date or dates (A)Â to the extent necessary or convenient to ensure that any
required supplement or amendment to the proxy statement is provided to shareholders or (B)Â in order to solicit
additional proxies from shareholders in favour of one or more of the proposals at the Meeting be approved (the
â€œAdjournment Proposalâ€). Â For Â Against Â Abstain 34,536,942 Â 5,464,832 Â 154,078 The information
furnished in this Report of Foreign Private Issuer on Form 6-K (this â€œReportâ€) is incorporated by reference into the
Companyâ€™s registration statements on Form S-8 (File No.Â 333-272559), Form F-1 (File No.Â 333-272552) and
Form F-3 (File Nos. 333-278430, 333-278431 and 333-279549), and any related prospectuses, as such registration
statements and prospectuses may be amended from time to time, and to be a part thereof from the date on which this
Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized. Â Â Â Apollomics Inc. Date: NovemberÂ 14,
2024 Â By: Â /s/ Guo-Liang Yu Â Â Â Guo-Liang Yu, Ph.D. Chief Executive Officer Â 3